Semaglutide, a popular anti-obesity drug, may come with a hidden cost: significant muscle loss, especially in women and older adults. A small study found that up to 40% of weight loss from ...

Tirzepatide outperformed semaglutide in simultaneously achieving four key therapeutic targets for type 2 diabetes.

Tirzepatide was superior to semaglutide in achieving standard and intensive cardiometabolic targets among patients with type 2 diabetes.

Among patients receiving semaglutide for obesity management, the risk for muscle loss may be higher in older adults and women, and a high protein intake can mitigate this risk.

The post Semaglutide Meal Plan Secrets: What Nobody Tells You About Eating on GLP-1 Medication appeared first on Organic Authority.

Neoadjuvant semaglutide showed no benefit in weight loss, diabetes remission or safety in a cohort of patients who underwent metabolic and bariatric surgery, according to study results published ...

People who took semaglutide over a slower, more flexible schedule were significantly less likely to experience nausea and to discontinue use.

GLP-1 RAs, semaglutide and tirzepatide, significantly lower dementia, stroke, and all-cause mortality risks in T2D and obesity patients compared to other antidiabetic drugs. The study included ...

We talk to Emile Adriambeloson about whether semaglutide could be used to treat Alzheimer’s disease.

Novo Nordisk saw 18% sales growth and 40% operating profit growth at constant currencies in the second quarter, but management reduced 2025 guidance to 8%-14% sales growth and 10%-16% operating ...

If all the Instagram posts and podcasts filling my feed are any indication, lots of 40- and 50-something women are spending lots of time thinking about weight.